Local pharma player Rameda saw its net income rise 43% y-o-y to EGP 86 mn in 1Q 2025, according to the company’s latest earnings release (pdf). Rameda’s revenues rose 90% y-o-y to reach EGP 866 mn during the quarter.

(Tap or click the headline above to read this story with all of the links to our background as well as external sources.)

Driving the growth was a 89% y-o-y jump in private sales to EGP 638.5 mn, a 57% rise in toll manufacturing revenue to EGP 55 mn, and 299% y-o-y growth in tender awards to EGP 116.8 mn. The pharma player also recorded a modest rise in export revenues, which came in at EGP 55.4 mn, marking a 4% y-o-y jump.

Price increases played a part: “This robust growth was driven by both volume and pricing increases compared to the previous year,” the report read. The company had received the green light to hike prices by 40-50% across its products in 2024.

What they said: “While we delivered excellent results in terms of sales, we also saw higher interest expense, a result of increasing our debt levels to support working capital needs and to complete our largest acquisition to date, Sugarlo. Despite this temporary impact, the decrease in interest rates is expected to positively impact our interest expense for the remainder of the year,” CFO Mahmoud Fayek said.

Tags: